Literature DB >> 16050866

The new medicare drug benefit: formularies and their potential effects on access to medications.

Haiden A Huskamp1, Nancy L Keating.   

Abstract

During congressional debate over the Medicare Part D prescription drug benefit, much attention was focused on nominal benefit design. Relatively little attention was paid to details about how plans would operate, such as the design of drug formularies. Yet, formularies will be important tools for controlling costs, and may be as important as nominal benefit design in determining enrollees' access to medications and out-of-pocket costs. We describe Part D plan incentives and how they may influence formulary design, and then provide recommendations for Part D formulary implementation. We encourage the Centers for Medicare & Medicaid Services (CMS) to develop standardized tools to provide physicians and patients with up-to-date and easily accessible information about covered drugs on each plan's formulary (perhaps via a central website) and a national set of easy-to-follow procedures for reconsideration and appeals. Such efforts should reduce administrative burden and better allow physicians to help patients obtain needed medications.

Entities:  

Mesh:

Year:  2005        PMID: 16050866      PMCID: PMC1403290          DOI: 10.1111/j.1525-1497.2005.0110.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  13 in total

1.  Provider perceptions of pharmacy management: lessons from the military health system.

Authors:  Peter A Glassman; Terri Tanielian; Katherine Harris; Ana Suarez; Melissa Bradley; Sid W Atkinson; William Davies; Thomas Williams
Journal:  Med Care       Date:  2004-04       Impact factor: 2.983

2.  Physicians' views of formularies: implications for Medicare drug benefit design.

Authors:  Bruce E Landon; James D Reschovsky; David Blumenthal
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Feb       Impact factor: 6.301

3.  The effect of prior-year health expenditures on health coverage plan choice.

Authors:  R P Ellis
Journal:  Adv Health Econ Health Serv Res       Date:  1985

4.  Predicting pharmacy costs and other medical costs using diagnoses and drug claims.

Authors:  Yang Zhao; Arlene S Ash; Randall P Ellis; John Z Ayanian; Gregory C Pope; Bruce Bowen; Lori Weyuker
Journal:  Med Care       Date:  2005-01       Impact factor: 2.983

5.  Physician perceptions of a national formulary.

Authors:  P A Glassman; C B Good; M E Kelley; M Bradley; M Valentino; J Ogden; K W Kizer
Journal:  Am J Manag Care       Date:  2001-03       Impact factor: 2.229

6.  Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Authors:  Sebastian Schneeweiss; Alexander M Walker; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Stephen B Soumerai
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

7.  Barriers to patient-physician communication about out-of-pocket costs.

Authors:  G Caleb Alexander; Lawrence P Casalino; Chien-Wen Tseng; Diane McFadden; David O Meltzer
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

8.  The effect of incentive-based formularies on prescription-drug utilization and spending.

Authors:  Haiden A Huskamp; Patricia A Deverka; Arnold M Epstein; Robert S Epstein; Kimberly A McGuigan; Richard G Frank
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

9.  Pharmacy benefits and the use of drugs by the chronically ill.

Authors:  Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

10.  Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Authors:  Sebastian Schneeweiss; Stephen B Soumerai; Malcolm Maclure; Colin Dormuth; Alexander M Walker; Robert J Glynn
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

View more
  6 in total

1.  Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.

Authors:  Haiden A Huskamp; Judith A Shinogle
Journal:  Psychiatr Serv       Date:  2005-09       Impact factor: 3.084

2.  Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007.

Authors:  Chi-Chuan Wang; Jae Kennedy; Lawrence J Cohen; David A Sclar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Medication use among Medicaid users of home and community-based services.

Authors:  Judith Shinogle; Joshua M Wiener
Journal:  Health Care Financ Rev       Date:  2006

4.  Family physician attitudes about prescribing using a drug formulary.

Authors:  L Suzanne Suggs; Parminder Raina; Amiram Gafni; Susan Grant; Kevin Skilton; Aimei Fan; Karen Szala-Meneok
Journal:  BMC Fam Pract       Date:  2009-10-16       Impact factor: 2.497

5.  Angiotensin receptor blockers on the formularies of Medicare drug plans.

Authors:  Walid F Gellad; Haiden A Huskamp; Kathryn A Phillips; Jennifer S Haas
Journal:  J Gen Intern Med       Date:  2007-05-15       Impact factor: 5.128

6.  Prescription drug use and expenditures among dually eligible beneficiaries.

Authors:  Ann D Bagchi; Dominick Esposito; James M Verdier
Journal:  Health Care Financ Rev       Date:  2007
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.